Skip to main content

Changes to Inpatient Dialysis MS-DRGs

Analysis  |  By Revenue Cycle Advisor  
   September 29, 2020

CMS created three new MS-DRGs whose relative weights will be calibrated to account for hemodialysis costs and will therefore be excluded from additional ESRD payments.

A version of this article was first published September 29, 2020, by HCPro's Revenue Cycle Advisor, a sibling publication to HealthLeaders.

Q: What changes to inpatient dialysis MS-DRGs did CMS finalize in the fiscal year 2021 Inpatient Prospective Payment System final rule?

A: CMS made several changes to reimbursement for inpatient dialysis.

Medicare will continue to pay an additional amount to hospitals for stays during which end-stage renal disease (ESRD) beneficiaries receive dialysis treatment, as long as ESRD beneficiary discharges constitute 10% or more of total Medicare discharges.

However, CMS created three new MS-DRGs whose relative weights will be calibrated to account for hemodialysis costs and will therefore be excluded from additional ESRD payments:

  1. MS-DRG 019 (Simultaneous Pancreas/Kidney Transplant with Hemodialysis)
  2. MS-DRG 650 (Kidney Transplant with Hemodialysis with MCC)
  3. MS-DRG 651 (Kidney Transplant with Hemodialysis without MCC)

CMS is also removing MS-DRGs 652 and 685 from the list of MS-DRGs excluded from additional ESRD payments.

For more informaiton, see "Note from the instructor: FY 2021 IPPS payment factors and related adjustments," by Judith L. Kares, JD.

Revenue Cycle Advisor combines all of HCPro's Medicare regulatory and reimbursement resources into one handy and easy-to-access portal. News is not just repeated from other sources. It is analyzed by our Medicare experts so professionals can comprehend any new rule and regulatory updates thoroughly. Learn more.


Get the latest on healthcare leadership in your inbox.